Correct Tacrolimus is a medication (immunosuppressant) used in the prevention and treatment of solid-organ transplant rejection. It is in the calcineurin-inhibitor class of medications. Tacrolimus can be administered with or without food. Tacrolimus is a narrow therapeutic index drug and requires regular blood tests to prevent adverse effects and toxicity. Therapeutic levels range from 5 to 20 mcg/mL, though 5 to 15 mcg/mL is often employed to alleviate toxicity while preventing rejection. Additional monitoring parameters include renal function, hepatic function, serum electrolytes (Mg, Phos, K), glucose, and blood pressure. Parameters should initially be measured two to three times a week post-operatively (transplant surgery), gradually decreasing as time passes, achieving target levels, and patient stabilization. The medication should be taken at the same time every day to prevent toxicity.
Fatigue and nausea can be initial signs of organ rejection and should be reported. Tacrolimus toxicity commonly presents as acute renal failure. Close monitoring of serum creatinine, GFR, and urine output is necessary for patients on tacrolimus. Toxicity may also present as the development of adverse effects such as tremors, electrolyte disturbances and headaches. No antidote exists currently to counter toxicity. Hemodialysis does not remove tacrolimus. Immunosuppressants can make a patient prone to fungal and viral infections increasing risk for infections (not bleeding). Patients should be monitored for infections.
Tacrolimus can cause angina pectoris, cardiac arrhythmias, hypertension, new-onset diabetes mellitus after transplant (NODAT), hypercalcemia, hyperkalemia, hyperlipidemia, hyperphosphatemia, hypertriglyceridemia, hyperuricemia, hypervolemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, metabolic acidosis, weight gain, abdominal pain, nausea, vomiting, diarrhea, alopecia, pruritis, rash, Arthralgia, muscle cramps, blurred vision and tinnitus.
Incorrect Tacrolimus is a medication (immunosuppressant) used in the prevention and treatment of solid-organ transplant rejection. It is in the calcineurin-inhibitor class of medications. Tacrolimus can be administered with or without food. Tacrolimus is a narrow therapeutic index drug and requires regular blood tests to prevent adverse effects and toxicity. Therapeutic levels range from 5 to 20 mcg/mL, though 5 to 15 mcg/mL is often employed to alleviate toxicity while preventing rejection. Additional monitoring parameters include renal function, hepatic function, serum electrolytes (Mg, Phos, K), glucose, and blood pressure. Parameters should initially be measured two to three times a week post-operatively (transplant surgery), gradually decreasing as time passes, achieving target levels, and patient stabilization. The medication should be taken at the same time every day to prevent toxicity.
Fatigue and nausea can be initial signs of organ rejection and should be reported. Tacrolimus toxicity commonly presents as acute renal failure. Close monitoring of serum creatinine, GFR, and urine output is necessary for patients on tacrolimus. Toxicity may also present as the development of adverse effects such as tremors, electrolyte disturbances and headaches. No antidote exists currently to counter toxicity. Hemodialysis does not remove tacrolimus. Immunosuppressants can make a patient prone to fungal and viral infections increasing risk for infections (not bleeding). Patients should be monitored for infections.
Tacrolimus can cause angina pectoris, cardiac arrhythmias, hypertension, new-onset diabetes mellitus after transplant (NODAT), hypercalcemia, hyperkalemia, hyperlipidemia, hyperphosphatemia, hypertriglyceridemia, hyperuricemia, hypervolemia, hypocalcemia, hypokalemia, hypomagnesemia, hyponatremia, hypophosphatemia, metabolic acidosis, weight gain, abdominal pain, nausea, vomiting, diarrhea, alopecia, pruritis, rash, Arthralgia, muscle cramps, blurred vision and tinnitus.